



ONE-YEAR OUTCOMES

PRASUGREL VS. TICAGRELOR IN AMI TREATED WITH PPCI

PRAGUE-18 STUDY

Zuzana Motovska, Petr Widimsky on behalf
of the PRAGUE-18 study investigators

Slide 1

1

Zuzana Motovska, 11/10/2017

PRAGUE-18 study

Head-to-head randomized comparison of Prasugrel and Ticagrelor in patients with AMI undergoing pPCI

Prasugrel and Ticagrelor dose regimens according to the guidelines, intended treatment duration 12 months

Purely academic project, no industrial support

INCLUSION CRITERIA

- STEMI /very high-risk NSTEMI
- Primary PCI strategy:
Immediate (<2 hs) CAG ± pPCI
- Signed informed consent

EXCLUSION CRITERIA

- History of stroke
- Serious bleeding < 6 months
- Indication for OAC
- Prerandomization clopidogrel ≥ 300 mg
- Body weight < 60 kg in a patient > 75 years
- Moderate-to-severe liver disease
- Treatment with potent CYP3A4 inhibitors
- Known hypersensitivity to prasugrel or ticagrelor

SAMPLE SIZE

Difference in primary EP 2.5%, a two-sided overall alpha level of 0.05, and a statistical power of 80%


Needed sample size: 1250 each arm

Enrollment terminated prematurely because of futility

Randomized 1230 patients; 634 Prasugrel / 596 Ticagrelor


FUTILITY ANALYSIS

COMPARISON OF REAL DIFFERENCES IN 1° EP
AND THE MINIMAL DIFFERENCE DETECTED AS
STATISTICALLY SIGNIFICANT BASED ON POWER
ANALYSIS



1° NET-CLINICAL ENDPOINT AT DAY 7

All-cause Death/reMI/urgent TVR/Stroke/Serious bleeding



SWITCH TO CLOPIDOGREL AFTER DISCHARGE

Prior the end of their hospitalization, every patient was informed


- about the out-of-pocket costs for study drugs
- about the clinical benefit of long-term prasugrel/ticagrelor compared to clopidogrel

The study protocol allowed patients, who were not willing to accept the costs associated with a study medication, to switch to clopidogrel

OBJECTIVE

- 1) Comparison of efficacy and safety between Prasugrel and Ticagrelor during the whole 12-months study period


- 1) Risk of major ischemic events related to an economically motivated post-discharge switch to clopidogrel



* The combined efficacy endpoint (EP) = Cardiovascular death, Non-fatal myocardial infarction, Stroke: Missing information in 19 patients were supplemented from national registries of the Institute of Health information and Statistics of the Czech Republic.

** For missing end-of-treatment data in 3 patients, a visit data were added for which treatment discontinuations were reported.

KEY EFFICACY ENDPOINT: CV Death/Non-fatal MI/Stroke




END POINTS

	Prasugrel	Ticagrelor	P-value
CV Death, Non-fatal MI or Stroke	42 (6.6%)	34 (5.7%)	0.503
Death from cardiovascular causes	21 (3.3%)	18 (3.0%)	0.769
Non-fatal myocardial infarction	19 (3.0%)	15 (2.5%)	0.611
Stroke	7 (1.1%)	4 (0.7%)	0.423
Definite stent thrombosis	7 (1.1%)	9 (1.5%)	0.535
Death from any cause	30 (4.7%)	25 (4.2%)	0.654
Bleeding	69 (10.9%)	66 (11.1%)	0.930
TIMI major	6 (0.9%)	4 (0.7%)	0.754
BARC \geq 3	15 (2.4%)	9 (1.5%)	0.308

SWITCH TO CLOPIDOGREL

	Prasugrel	Ticagrelor	P-value
Economic reasons (Patient cost sharing)	216 (34.1%)	265 (44.4%)	0.003
Chronic anticoagulation therapy	19 (3.0%)	21 (3.5%)	0.999
Adverse effects	31 (4.9%)	24 (4.0%)	0.999
Other	44 (7.0%)	39 (6.5%)	0.999

Time distribution of economically motivated switches to clopidogrel after discharge



		HR (95% CI)	P-value
Risk of ischemic endpoint *	Economically motivated switch (N=481)	0.433 (0.210–0.894)	0.024
	Switch from other reasons (N=178)	3.420 (1.823–6.415)	<0.001
Risk of bleeding	Economically motivated switch (N=481)	0.416 (0.246–0.701)	0.001

* Cardiovascular death, non-fatal myocardial infarction or stroke.

The hazard ratio was based on the Cox proportional hazard model with time dependent covariates

Significant differences in patient- and procedure related characteristics and economically motivated switch to clopidogrel

	SWITCH TO CLOPIDOGREL		P-value
	No	Yes	
BMI > 30	223 (29.8%)	172 (35.8%)	0.029
ECG			
Left bundle branch block	17 (2.3%)	1 (0.2%)	0.002
Bundle branch block	33 (4.4%)	7 (1.5%)	0.005
Killip classification			
I	642 (85.7%)	443 (92.1%)	
II	59 (7.9%)	23 (4.8%)	0.004
III	11 (1.5%)	6 (1.2%)	
IV	37 (4.9%)	9 (1.9%)	
I	642 (85.7%)	443 (92.1%)	<0.001
≥ II	107 (14.3%)	38 (7.9%)	
History			
Hypertension	359 (47.9%)	271 (56.3%)	0.004
Smoker	467 (62.3%)	331 (68.8%)	0.023
Left main disease	36 (4.8%)	5 (1.0%)	<0.001
Postprocedural result – suboptimal + failure	44 (5.9%)	15 (3.1%)	0.028

CONCLUSIONS

- 1) Prasugrel and Ticagrelor are similarly effective and safe during the first year after MI treated with pPCI

- 1) Economically motivated, early post-discharge switch to clopidogrel, when approved by treating physicians, was not associated with increased risk of ischemic events

Accepted Manuscript



One-year Outcomes of Prasugrel Versus Ticagrelor In Acute Myocardial Infarction Treated With Primary Angioplasty: The PRAGUE-18 Study

Zuzana Motovska, MD, PhD, Ota Hlinomaz, MD, CSc, Petr Kala, MD, PhD, Milan Hromadka, MD, PhD, Jiri Knot, MD, PhD, Ivo Varvarovsky, MD, PhD, Jaroslav Dusek, MD, PhD, Jiri Jarkovsky, MSc, PhD, Roman Miklik, MD, PhD, Richard Rokyta, MD, PhD, Frantisek Tousek, MD, Petra Kramarikova, Mgr, Michal Svoboda, MSc, Bohumil Majtan, MD, Stanislav Simek, MD, CSc, Marian Branny, MD, PhD, Jan Mrozek, MD, Pavel Cervinka, MD, PhD, Jiri Ostransky, MD, Petr Widimsky, MD, DrSc, PRAGUE-18 Study Group

Journal of the American College of Cardiology

ELSEVIER


PII: S0735-1097(17)41524-5

DOI: [10.1016/j.jacc.2017.11.008](https://doi.org/10.1016/j.jacc.2017.11.008)

Reference: JAC 24432

Back-up slides

	Patients	Ischemic endpoint		HR (95% CI)	P-value for interaction
		Prasugrel	Ticagrelor		
Total					
	N=1230	42 (6.6%)	34 (5.7%)	1.167 (0.742–1.835)	-
Age					
<75	N=1108	37 (6.4%)	27 (5.1%)	1.260 (0.767–2.069)	
≥75	N=122	5 (9.3%)	7 (10.3%)	0.873 (0.277–2.751)	0.565
Killip classification					
I–III	N=1184	32 (5.3%)	25 (4.3%)	1.214 (0.720–2.049)	
IV	N=46	10 (40.0%)	9 (42.9%)	0.886 (0.360–2.182)	0.564
I+II	N=1167	28 (4.7%)	23 (4.0%)	1.158 (0.667–2.010)	
III+IV	N=63	14 (40.0%)	11 (39.3%)	1.000 (0.454–2.204)	0.772
Chronic kidney disease					
No	N=1214	41 (6.6%)	34 (5.8%)	1.138 (0.722–1.793)	-
Yes	N=16	1 (12.5%)	0 (0.0%)	-	
Diabetes					
No	N=980	31 (6.1%)	23 (4.9%)	1.257 (0.733–2.156)	
Yes	N=250	11 (8.7%)	11 (8.9%)	0.998 (0.433–2.302)	0.642
Weight					
< 60	N=27	1 (7.7%)	1 (7.1%)	1.038 (0.065–16.599)	
≥ 60	N=1203	41 (6.6%)	33 (5.7%)	1.173 (0.742–1.855)	0.926
STEMI					
No	N=72	2 (5.6%)	4 (11.1%)	0.468 (0.086–2.558)	
Yes	N=1158	40 (6.7%)	30 (5.3%)	1.259 (0.784–2.021)	0.274



CLINICAL SIGNIFICANCE NUMBER NEEDED TO TREAT

Preference of Prasugrel/Ticagrelor over Clopidogrel

TRITON Primary ischemic EP Difference: **2.2%** NNT: **46**

PLATO Primary ischemic EP Difference: **1.9%** NNT: **53**


Non-preference between Prasugrel/Ticagrelor

PRAGUE-18


Primary Net-clinical EP difference: **0.1%** NNT: **1158**

Like PLATO/TRITON Primary EP Difference: **0.3%** NNT: **333**


CV Death/Spontaneous MI/Stroke




CV Death/Spont. + Peri-PCI MI/Stroke




CV DEATH/SPONT. + PERI-PCI MI/STROKE




ALL-CAUSE DEATH




CARDIOVASCULAR DEATH




NON-FATAL MYOCARDIAL INFARCTION



SAFETY




Time distribution of economically motivated switches to clopidogrel after discharge




BENEFIT OF DAPT IN STEMI and pPCI

**“Spontaneous” primary endpoint
(CV death, nonprocedural MI, stroke)
among primary PCI patients**



TRITON trial

**Primary endpoint
(CV death, MI, stroke) among primary PCI
patients**



PLATO trial

J Am Coll Cardiol Intv 2014;7:604

Heart 2016;102:617

**AHA SCIENTIFIC SESSIONS
Anaheim 2017**

PRAGUE – 18 STUDY

Weighing Benefits and Risks — The FDA's Review of Prasugrel

Ellis F. Unger, M.D.

Patients with Outcome Events in TRITON-TIMI 38.*				
Patient Group at Presentation	Treatment Group		Relative Risk Reduction (95% CI)†	P Value
	Prasugrel	Clopidogrel	%	
Unstable angina and non-ST-segment-elevation myocardial infarction				
No. of patients	5044	5030		
End-point event (% of patients)				
Cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke	9.3	11.2	18.0 (7.3 to 27.4)	0.002
Cardiovascular death	1.8	1.8	2.1 (-30.9 to 26.8)	0.89
Nonfatal myocardial infarction	7.1	9.2	23.9 (12.7 to 33.7)	<0.001
Nonfatal stroke	0.8	0.8	2.1 (-51.3 to 36.7)	0.92
ST-segment-elevation myocardial infarction				
No. of patients	1769	1765		
End-point event (% of patients)				
Cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke	9.8	12.2	20.7 (3.2 to 35.1)	0.02
Cardiovascular death	2.4	3.3	26.2 (-9.4 to 50.3)	0.13
Nonfatal myocardial infarction	6.7	8.8	25.4 (5.2 to 41.2)	0.02
Nonfatal stroke	1.2	1.1	-9.7 (-104 to 41.0)	0.77
Overall				
No. of patients	6813	6795		
End-point event (% of patients)				
Cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke	9.4	11.5	18.8 (9.8 to 26.8)	<0.001
Cardiovascular death	2.0	2.2	11.4 (-11.8 to 29.9)	0.31
Nonfatal myocardial infarction	7.0	9.1	24.3 (14.7 to 32.8)	<0.001
Nonfatal stroke	0.9	0.9	-1.6 (-45.1 to 28.8)	0.93

ment. The FDA made sure that prasugrel's label clearly articulates the balance between efficacy and risk — a balance that physicians will need to assess carefully when choosing treatment for individual patients.

NEJM 2009